I hold a Ph.D. in Human Genetics, backed by comprehensive advanced training at the University of Nebraska Medical Center, where I served as a Senior Scientist. With over ten years of experience in molecular oncology, immunogenomics, and hematopathology, my research delves into the complex genetic, epigenetic, and immune mechanisms that drive aggressive lymphomas, such as HGBCL-NOS, molecular Burkitt lymphoma, mantle cell lymphoma, and nodal TFH-derived PTCLs like AITL. Through my work, I have made impactful contributions in understanding how the loss of TP53 and PTEN triggers TH2 polarization and activates the MYC/STAT3 pathway in PTCL, highlighting these factors as promising therapeutic targets. Utilizing CRISPR-edited models, in vitro CD4+ T-cell polarization systems, and murine models, I explore immune cell fate and oncogenic signaling with precision. In addition to my research, I lead translational initiatives that leverage ctDNA/cfDNA-based biomarkers and phosphoproteomics to uncover new therapeutic targets for CAR-T and NK-CAR therapies. My findings have been published in prestigious journals including Cell, Blood, JCO, CCR, AJH and Science Advances. I am deeply committed to advancing precision medicine through collaborative research endeavors and fostering the next generation of scientists through mentorship.